GILEAD SCIENCES, INC. Tax Benefit from Stock Options Exercised (Deprecated 2012-01-31)
GILEAD SCIENCES, INC. (GILD) reported Tax Benefit from Stock Options Exercised (Deprecated 2012-01-31) of $18.15 million for the 3-month period ending 2012-03-31, per its 10-Q filed 2012-05-04.
Discontinued › Expense Statement › Income Tax
us-gaap:TaxBenefitFromStockOptionsExercised · last filed 2012-05-04
- GILEAD SCIENCES, INC. tax benefit from stock options exercised (deprecated 2012-01-31) for the quarter ending 2012-03-31 was $18.15M, a 49.58% increase year-over-year.
- GILEAD SCIENCES, INC. tax benefit from stock options exercised (deprecated 2012-01-31) for the quarter ending 2011-12-31 was $10.66M, a 12.26% decline year-over-year.
- GILEAD SCIENCES, INC. tax benefit from stock options exercised (deprecated 2012-01-31) for the quarter ending 2011-09-30 was $8.78M, a 21.61% increase year-over-year.
- GILEAD SCIENCES, INC. tax benefit from stock options exercised (deprecated 2012-01-31) for the quarter ending 2011-06-30 was $5.66M, a 48.81% decline year-over-year.
- GILEAD SCIENCES, INC. tax benefit from stock options exercised (deprecated 2012-01-31) for fiscal 2011 was $37.23M, a 54.64% decline from fiscal 2010.
- GILEAD SCIENCES, INC. tax benefit from stock options exercised (deprecated 2012-01-31) for fiscal 2010 was $82.09M, a 7.11% decline from fiscal 2009.
- GILEAD SCIENCES, INC. tax benefit from stock options exercised (deprecated 2012-01-31) for fiscal 2009 was $88.37M, a 57.82% decline from fiscal 2008.
- GILEAD SCIENCES, INC. tax benefit from stock options exercised (deprecated 2012-01-31) for fiscal 2008 was $209.52M, a 89.31% increase from fiscal 2007.
| Period end | Tax Benefit from Stock Options Exercised (Deprecated 2012-01-31) 3 month | Tax Benefit from Stock Options Exercised (Deprecated 2012-01-31) 6 month | Tax Benefit from Stock Options Exercised (Deprecated 2012-01-31) 9 month | Tax Benefit from Stock Options Exercised (Deprecated 2012-01-31) 12 month |
|---|---|---|---|---|
| 2012-03-31 | $18.15M 10-Q · filed 2012-05-04 | $28.81M derived: sum of 2 quarters · filed 2012-05-04 | $37.59M derived: sum of 3 quarters · filed 2012-05-04 | $43.25M derived: sum of 4 quarters · filed 2012-05-04 |
| 2011-12-31 | $10.66M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-23 | $19.43M derived: sum of 2 quarters · filed 2012-02-23 | $25.09M derived: sum of 3 quarters · filed 2012-02-23 | $37.23M 10-K · filed 2012-02-23 |
| 2011-09-30 | $8.78M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-04 | $14.44M derived: sum of 2 quarters · filed 2011-11-04 | $26.57M 10-Q · filed 2011-11-04 | $38.72M derived: sum of 4 quarters · filed 2012-05-04 |
| 2011-06-30 | $5.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2011-08-05 | $17.80M 10-Q · filed 2011-08-05 | $29.94M derived: sum of 3 quarters · filed 2012-05-04 | $37.16M derived: sum of 4 quarters · filed 2012-05-04 |
| 2011-03-31 | $12.14M 10-Q · filed 2012-05-04 | $24.28M derived: sum of 2 quarters · filed 2012-05-04 | $31.50M derived: sum of 3 quarters · filed 2012-05-04 | $42.56M derived: sum of 4 quarters · filed 2012-05-04 |
| 2010-12-31 | $12.15M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-23 | $19.36M derived: sum of 2 quarters · filed 2012-02-23 | $30.42M derived: sum of 3 quarters · filed 2012-02-23 | $82.09M 10-K · filed 2012-02-23 |
| 2010-09-30 | $7.22M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-04 | $18.27M derived: sum of 2 quarters · filed 2011-11-04 | $69.94M 10-Q · filed 2011-11-04 | $92.06M derived: sum of 4 quarters · filed 2012-02-23 |
| 2010-06-30 | $11.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2011-08-05 | $62.72M 10-Q · filed 2011-08-05 | $84.85M derived: sum of 3 quarters · filed 2012-02-23 | $112.25M derived: sum of 4 quarters · filed 2012-02-23 |
| 2010-03-31 | $51.66M 10-Q · filed 2011-05-09 | $73.79M derived: sum of 2 quarters · filed 2012-02-23 | $101.20M derived: sum of 3 quarters · filed 2012-02-23 | $116.43M derived: sum of 4 quarters · filed 2012-02-23 |
| 2009-12-31 | $22.13M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-23 | $49.53M derived: sum of 2 quarters · filed 2012-02-23 | $64.76M derived: sum of 3 quarters · filed 2012-02-23 | $88.37M 10-K · filed 2012-02-23 |
| 2009-09-30 | $27.41M derived: 10-Q 9 month − 10-Q 6 month · filed 2010-11-08 | $42.64M derived: sum of 2 quarters · filed 2010-11-08 | $66.24M 10-Q · filed 2010-11-08 | $106.43M derived: sum of 4 quarters · filed 2011-02-28 |
| 2009-06-30 | $15.23M derived: 10-Q 6 month − 10-Q 3 month · filed 2010-08-09 | $38.84M 10-Q · filed 2010-08-09 | $79.03M derived: sum of 3 quarters · filed 2011-02-28 | $118.98M derived: sum of 4 quarters · filed 2011-02-28 |
| 2009-03-31 | $23.60M 10-Q · filed 2010-05-10 | $63.80M derived: sum of 2 quarters · filed 2011-02-28 | $103.75M derived: sum of 3 quarters · filed 2011-02-28 | |
| 2008-12-31 | $40.19M derived: 10-K 12 month − 10-Q 9 month · filed 2011-02-28 | $80.15M derived: sum of 2 quarters · filed 2011-02-28 | $209.52M 10-K · filed 2011-02-28 | |
| 2008-09-30 | $39.96M derived: 10-Q 9 month − 10-Q 6 month · filed 2009-11-05 | $169.33M 10-Q · filed 2009-11-05 | ||
| 2008-06-30 | $129.37M 10-Q · filed 2009-08-05 | |||
| 2007-12-31 | $110.68M 10-K · filed 2010-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |